The founder, Dr. Shuhui Chen, is a former Chief Scientist at WuXi AppTec with extensive drug development experience. He has successfully advanced numerous clinical programs and contributed to over 100 IND filings for Chinese clients, earning a strong reputation in the industry. Driven by clinical needs, the company focuses on high-potential areas such as oncology, immunology, and metabolism, pursuing R&D projects with manageable risks and significant market potential.

The founder, Professor Chuan He, is a world-renowned expert in RNA post-transcriptional modifications, a tenured professor in the Department of Chemistry at the University of Chicago, a member of the American Academy of Arts and Sciences, a Wolf Prize laureate, and a Howard Hughes Medical Institute Investigator. The company focuses on the field of RNA post-transcriptional modifications, targeting high-value molecules with significant unmet clinical needs and market potential to develop first-in-class small-molecule drugs.

The company is a deep-tech enterprise commercializing scientific achievements from the academician team of Guangzhou National Laboratory. Led by Prof Tao Xu, it operates as a national-level platform and serves as a key translational project of his team. Prof Tao Xu is the Deputy Director of Guangzhou National Laboratory, Vice Chairman of the Chinese Peasants and Workers Democratic Party, and an expert in super-resolution imaging and ultrasensitive detection. The company leverages China’s most comprehensive professional microfluidic technology platform to independently develop life science instruments and biopharmaceutical equipment.

The founder, Dr. Qing Dong, previously served as Chief Scientist at Hengrui Pharmaceuticals and has a proven track record of successful entrepreneurial ventures and exits. Founded in 2023, the company is a US-based innovative biotech focused on the immunology and oncology fields, dedicated to developing best-in-class small-molecule drugs.

Founded in 2021, it is an innovative biotech company based in San Diego, US. Company founder, Dr. Qing Dong, previously served as Chief Scientist at Hengrui Pharmaceuticals. Within two years of its establishment, the company was fully acquired by the Gilead Sciences for $960 million, making it one of the top 10 global small-molecule drug deals in 2023.

The company is one of the few in China focused on developing medical-grade implantable wireless brain-computer interface (BCI) technology. Its founder, Dr. Xiaojian Li, is a senior engineer and professor at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. He serves as an advisory expert on implantable BCI devices for the National Medical Products Administration’s Center for Medical Device Evaluation and is a member of the Brain-Computer Interface Standardization Expert Group of the Ministry of Industry and Information Technology’s China Information Standardization Committee.

The company is incubated by global CRO giant IQVIA in China, combining a global innovation perspective with localized innovative technologies. Its founder, Dr. Zhen Wang, serves as Senior Advisor to the President of IQVIA Asia-Pacific and has extensive experience in corporate digitalization, AI-driven innovation, and healthcare strategic consulting. The founding team possesses over 20 years of global clinical operations and data management expertise.

The founder, Dr. Huaqiong Shen, previously served as Chief Medical Officer at Hengrui Pharmaceuticals and CEO of I-Mab Biopharma, leading the company to a successful U.S. IPO. The company is a biotech focused on developing innovative therapies for central nervous system disorders, with dual platforms for adeno-associated virus (AAV) gene therapy and small-molecule drug development.

The founder and Chief Scientist, Dr. Baoquan Ding, studied under Professor Nadrian Seeman, the father of DNA nanotechnology. The company focuses on researching nucleic acid self-assembling drug carriers and is dedicated to developing a next-generation nucleic acid self-assembly drug delivery platform. This platform aims to achieve efficient, targeted, and safe delivery of nucleic acid-based, small-molecule, and macromolecular drugs, with the potential to create high-value innovative therapies in the field of drug delivery.